Immunocore Holdings Stock Today
| IMCR Stock | USD 30.43 1.72 5.99% |
PerformanceWeak
| Odds Of DistressLow
|
Immunocore Holdings is selling at 30.43 as of the 20th of March 2025; that is 5.99 percent increase since the beginning of the trading day. The stock's lowest day price was 28.71. Immunocore Holdings has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. The company has 50.07 M outstanding shares of which 7.42 M shares are currently shorted by private and institutional investors with about 38.58 trading days to cover. More on Immunocore Holdings
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Immunocore Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmunocore Holdings can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunocore Holdings' financial leverage. It provides some insight into what part of Immunocore Holdings' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunocore Holdings (IMCR) is traded on NASDAQ Exchange in USA. It is located in 92 Park Drive, Abingdon, United Kingdom, OX14 4RY and employs 493 people. Immunocore Holdings is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.44 B. Immunocore Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 50.07 M outstanding shares of which 7.42 M shares are currently shorted by private and institutional investors with about 38.58 trading days to cover.
Immunocore Holdings currently holds about 208.06 M in cash with 26.06 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.74.
Check Immunocore Holdings Probability Of Bankruptcy
Ownership AllocationImmunocore Holdings has a total of 50.07 Million outstanding shares. The majority of Immunocore Holdings outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunocore Holdings to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunocore Holdings. Please pay attention to any change in the institutional holdings of Immunocore Holdings as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immunocore Ownership Details
Immunocore Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-12-31 | 1.2 M | |
| Fiera Capital Corporation | 2024-12-31 | 780 K | |
| Citigroup Inc | 2024-12-31 | 632.9 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 604.9 K | |
| Groupama Asset Management | 2024-12-31 | 600 K | |
| Millennium Management Llc | 2024-12-31 | 573.4 K | |
| Deep Track Capital, Lp | 2024-12-31 | 519.4 K | |
| Principal Financial Group Inc | 2024-12-31 | 502.9 K | |
| Massachusetts Financial Services Company | 2024-12-31 | 459 K | |
| T. Rowe Price Investment Management,inc. | 2024-12-31 | 6.7 M | |
| Wellington Management Company Llp | 2024-12-31 | 6.6 M |
Immunocore Holdings Historical Income Statement
Immunocore Stock Against Markets
Immunocore Holdings Corporate Management
| Tina Leger | Executive Officer | Profile | |
| Sbastien Desprez | Head Communications | Profile | |
| Debra Nielsen | Chief Staff | Profile | |
| JD Esq | Chief Officer | Profile | |
| Annelise Vuidepot | CTO Research | Profile | |
| Brian MBA | CFO Strategy | Profile | |
| Amy JudgePrein | Chief Officer | Profile |
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.